Relypsa Inc. (NASDAQ:RLYP) shares rose 4.8% during trading on Monday . The company traded as high as $21.21 and last traded at $21.14, with a volume of 2,443,787 shares traded. The stock had previously closed at $20.17.

RLYP has been the topic of several research analyst reports. Zacks Investment Research lowered Relypsa from a “hold” rating to a “sell” rating in a research note on Tuesday, March 22nd. Vetr raised Relypsa from a “strong sell” rating to a “strong-buy” rating and set a $22.45 price objective on the stock in a research note on Wednesday, June 22nd. Citigroup Inc. reaffirmed a “buy” rating and issued a $30.00 price objective (down from $38.00) on shares of Relypsa in a research note on Wednesday, March 16th. Raymond James Financial Inc. initiated coverage on Relypsa in a research note on Friday, April 1st. They issued a “market perform” rating on the stock. Finally, Brean Capital initiated coverage on Relypsa in a research note on Tuesday, March 29th. They issued a “buy” rating and a $26.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $34.53.

The firm’s market capitalization is $906.13 million. The firm has a 50 day moving average price of $18.27 and a 200 day moving average price of $17.92.

Relypsa (NASDAQ:RLYP) last announced its earnings results on Wednesday, May 4th. The company reported ($1.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.46) by $0.20. During the same quarter in the prior year, the company earned ($0.78) earnings per share. The business earned $12.40 million during the quarter, compared to the consensus estimate of $6.88 million. Analysts anticipate that Relypsa Inc. will post ($5.91) EPS for the current year.

A number of institutional investors have made changes to their positions in RLYP. ProShare Advisors LLC raised its position in shares of Relypsa by 9.9% in the fourth quarter. ProShare Advisors LLC now owns 38,272 shares of the company’s stock worth $1,085,000 after buying an additional 3,445 shares in the last quarter. Oppenheimer & Co. Inc. raised its position in shares of Relypsa by 122.7% in the fourth quarter. Oppenheimer & Co. Inc. now owns 38,455 shares of the company’s stock worth $1,090,000 after buying an additional 21,189 shares in the last quarter. Nationwide Fund Advisors raised its position in shares of Relypsa by 0.6% in the fourth quarter. Nationwide Fund Advisors now owns 42,287 shares of the company’s stock worth $1,198,000 after buying an additional 272 shares in the last quarter. American Century Companies Inc. acquired a new position in shares of Relypsa during the fourth quarter worth $1,299,000. Finally, California State Teachers Retirement System raised its position in shares of Relypsa by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 60,422 shares of the company’s stock worth $1,712,000 after buying an additional 1,084 shares in the last quarter.

Relypsa, Inc is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of polymer-based drugs to treat conditions that are often overlooked and undertreated, but that can have a serious impact on patients’ lives and even be life-threatening. The Company’s first drug candidate is Veltassa (patiromer) for oral suspension, or Veltassa, for the treatment of hyperkalemia.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.